

# Neurogenic Shock

From HumanResearchWiki

## Contents

- 1 Introduction
- 2 Clinical Priority and Clinical Priority Rationale by Design Reference Mission
- 3 Initial Treatment Steps During Space Flight
- 4 Capabilities Needed for Diagnosis
- 5 Capabilities Needed for Treatment
- 6 Associated Gap Reports
- 7 Other Pertinent Documents
- 8 List of Acronyms
- 9 References
- 10 Last Update

## Introduction

Shock is a generalized medical state characterized by inadequate tissue perfusion leading to poor oxygenation of the tissue. Neurogenic shock specifically results from severe injury to the spinal cord or central nervous system. Sympathetic innervation from the cervical or upper thoracic spinal cord to the heart and peripheral blood vessels is lost. As a result, the patient experiences decreased heart rate (bradycardia) and vasodilation leading to severe hypotension. Treatment is a multi-faceted approach. Treatment is based on maintaining adequate tissue perfusion and oxygenation. Therefore intravenous (IV) fluids are needed, along with drugs to reverse the underlying cause. Vasopressors (i.e., phenylephrine) and atropine are needed for additional blood pressure and cardiac rate support. Neurogenic shock is a medical emergency.

## Clinical Priority and Clinical Priority Rationale by Design Reference Mission

*One of the inherent properties of space flight is a limitation in available mass, power, and volume within the space craft. These limitations mandate prioritization of what medical equipment and consumables are manifested for the flight, and which medical conditions would be addressed. Therefore, clinical priorities have been assigned to describe which medical conditions will be allocated resources for diagnosis and treatment. “Shall” conditions are those for which diagnostic and treatment capability must be provided, due to a high likelihood of their occurrence and severe consequence if the condition were to occur and no treatment was available. “Should” conditions are those for which diagnostic and treatment capability should be provided if mass/power/volume limitations allow. Conditions were designated as “Not Addressed” if no specific diagnostic and/or treatment capability are expected to be manifested, either due to a very low likelihood of occurrence or other limitations (for example, in medical training, hardware, or consumables) that would preclude treatment. Design Reference Missions (DRMs) are proposed future missions designated by a set of assumptions that encompass parameters such as destination, length of mission, number of crewmembers, number of Extravehicular Activities (EVAs), and anticipated level of*

care. The clinical priorities for all medical conditions on the Exploration Medical Condition List (EMCL) can be found here ([https://humanresearchwiki.jsc.nasa.gov/index.php?title=Category:All\\_DRM](https://humanresearchwiki.jsc.nasa.gov/index.php?title=Category:All_DRM)). The EMCL document may be accessed here ([https://humanresearchwiki.jsc.nasa.gov/images/6/62/EMCL\\_RevC\\_2013.pdf](https://humanresearchwiki.jsc.nasa.gov/images/6/62/EMCL_RevC_2013.pdf)).

Design Reference Mission	Clinical Priority	Clinical Priority Rationale
Lunar sortie mission  Assumptions: <ul style="list-style-type: none"> <li>■ 4 crewmembers (3 males, 1 female)</li> <li>■ 14 days total</li> <li>■ 4 EVAs/crewmember</li> <li>■ <u>Level of Care 3</u></li> </ul>	Not Addressed	The complexity of caring for a crewmember with neurogenic shock is beyond the scope of the planned medical resources. Although it could cause loss of life and disruption of the mission, the likelihood of its occurrence is low.
Lunar outpost mission  Assumptions: <ul style="list-style-type: none"> <li>■ 4 crewmembers (3 males, 1 female)</li> <li>■ 180 days total</li> <li>■ 90 EVAs/crewmember</li> <li>■ <u>Level of Care 4</u></li> </ul>	Not Addressed	The complexity of caring for a crewmember with neurogenic shock is beyond the scope of the planned medical resources. Although it could cause loss of life and disruption of the mission, the likelihood of its occurrence is low.
Near-Earth Asteroid (NEA) mission  Assumptions: <ul style="list-style-type: none"> <li>■ 3 crewmembers (2 males, 1 female)</li> <li>■ 395 days total</li> <li>■ 30 EVAs/crewmember</li> <li>■ <u>Level of Care 5</u></li> </ul>	Not Addressed	The complexity of caring for a crewmember with neurogenic shock is beyond the scope of the planned medical resources. Although it could cause loss of life and disruption of the mission, the likelihood of its occurrence is low.

## Initial Treatment Steps During Space Flight

A link is provided to a prior version of the International Space Station (ISS) Medical Checklist, which outlines the initial diagnostic and treatment steps recommended during space flight for various conditions which may be encountered onboard the ISS. Further diagnostic and treatment procedures beyond the initial steps outlined in the Medical Checklist are then recommended by the ground-based Flight Surgeon, depending on the clinical scenario.

*Please note that this version does not represent current diagnostic or treatment capabilities available on the ISS. While more recent versions of this document are not accessible to the general public, the provided version of the checklist can still provide a general sense of how medical conditions are handled in the space flight environment. Medical Checklists will be developed for exploration missions at a later point in time.*

Please note this file is over 20 megabytes (MB) in size, and may take a few minutes to fully download.

ISS Medical Checklist ([http://www.nasa.gov/centers/johnson/pdf/163533main\\_ISS\\_Med\\_CL.pdf](http://www.nasa.gov/centers/johnson/pdf/163533main_ISS_Med_CL.pdf))

## Capabilities Needed for Diagnosis

*The following is a hypothetical list of capabilities that would be helpful in diagnosis. It does not necessarily represent the current capabilities available onboard current spacecraft or on the ISS, and may include capabilities that are not yet feasible in the space flight environment.*

- Crew medical restraint system
- Vital signs measurement capability (blood pressure, pulse, respiratory rate, temperature, pulse oximetry)
- Gloves (sterile and non-sterile)
- Otoscope/ophthalmoscope (for eye and ear exam)
- Auscultation device (such as a stethoscope)
- Imaging modality [such as a camera, ultrasound, Magnetic Resonance Imaging (MRI), Computed Tomography (CT)]
- Electrocardiograph (ECG) monitor
- Blood analysis (such as blood gases, chemistries, etc.)

## Capabilities Needed for Treatment

*The following is a hypothetical list of capabilities that would be helpful in treatment. It does not necessarily represent the current capabilities available onboard current spacecraft or on the ISS, and may include capabilities that are not yet feasible in the space flight environment.*

- Crew medical restraint system (neck and spine restraints)
- Assisted Ventilation Equipment (Ambu bag and mask and mechanical ventilator)
- Supplemental oxygen
- Intubation kit
- Central line kit
- IV start and administration kit
- Intravascular volume replacement (such as IV fluids)
- IV pump or pressure infuser
- Medication delivery device (such as a Carpuject)
- Sharps container
- Analgesics (non-narcotic, narcotic, oral, injectable)

- Pharmacy(Adrenergic agonists and parasympathetic antagonists) Foley catheter
- Urine collection bags

## Associated Gap Reports

*The NASA Human Research Program (HRP) identifies gaps in knowledge about the health risks associated with human space travel and the ability to mitigate such risks. The overall objective is to identify gaps critical to human space missions and close them through research and development. The gap reports that are applicable to this medical condition are listed below. A link to all of the HRP gaps can be found here (<http://humanresearchroadmap.nasa.gov/Gaps/>).*

- 2.01 - We do not know the quantified health and mission outcomes due to medical events during exploration missions.
- 2.02 - We do not know how the inclusion of a physician crew medical officer quantitatively impacts clinical outcomes during exploration missions.
- 3.01 - We do not know the optimal training methods for in-flight medical conditions identified on the Exploration Medical Condition List taking into account the crew medical officer's clinical background. (Closed)
- 3.03 - We do not know which emerging technologies are suitable for in-flight screening, diagnosis, and treatment during exploration missions.
- 4.01 - We do not have the capability to provide a guided medical procedure system that integrates with the medical system during exploration missions.
- 4.02 - We do not have the capability to provide non-invasive medical imaging during exploration missions.
- 4.04 - We do not have the capability to deliver supplemental oxygen to crew members while minimizing local and cabin oxygen build-up during exploration missions.
- 4.05 - We do not have the capability to measure laboratory analytes in a minimally invasive manner during exploration missions.
- 4.09 - We do not have the capability to provide medical suction and fluid containment during exploration missions.
- 4.12 - We do not have the capability to generate and utilize sterile intravenous fluid from potable water during exploration missions.
- 4.14 - We do not have the capability to track medical inventory in a manner that integrates securely with the medical system during exploration missions.
- 4.15 - Lack of medication usage tracking system that includes automatic time stamping and crew identification
- 4.17 - We do not have the capability to package medications to preserve stability and shelf-life during exploration missions.
- 4.19 - We do not have the capability to monitor physiological parameters in a minimally invasive manner during exploration missions.
- 4.23 - We do not have the capability to auscultate, transmit, and record body sounds during exploration missions.
- 4.24 - Lack of knowledge regarding the treatment of conditions on the Space Medicine Exploration Medical Condition List in remote, resource poor environments (Closed)
- 4.27 - We do not have the capability to sterilize medical equipment during exploration missions.
- 5.01 - We do not have the capability to comprehensively manage medical data during exploration missions.

## Other Pertinent Documents

### List of Acronyms

C	
CT	Computed Tomography

<b>D</b>	
<a href="#">DRM</a>	Design Reference Mission
<b>E</b>	
<a href="#">ECG</a>	Electrocardiograph
<a href="#">EMCL</a>	Exploration Medical Condition List
<a href="#">EVA</a>	Extravehicular Activity
<b>H</b>	
<a href="#">HRP</a>	Human Research Program
<b>I</b>	
<a href="#">ISS</a>	International Space Station
<a href="#">IV</a>	Intravenous
<b>M</b>	
<a href="#">MB</a>	Megabyte
<a href="#">MRI</a>	Magnetic Resonance Imaging
<b>N</b>	
<a href="#">NASA</a>	National Aeronautics and Space Administration
<a href="#">NEA</a>	Near Earth Asteroid
<b>S</b>	
<a href="#">SCI</a>	Spinal Cord Injury

## References

## Last Update

This topic was last updated on 8/12/2014 (Version 2).

Retrieved from "[https://humanresearchwiki.jsc.nasa.gov/index.php?title=Neurogenic\\_Shock&oldid=5673](https://humanresearchwiki.jsc.nasa.gov/index.php?title=Neurogenic_Shock&oldid=5673)"

Category: Medical Conditions

- 
- This page was last modified on 12 August 2014, at 15:50.